SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : IDPH--Positive preliminary results for pivotal trial of ID
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Richard Belanger who wrote (943)6/3/1997 6:31:00 PM
From: Brad C. Dunlap   of 1762
 
Hi Richard, certainly for any new drug there are many unknowns and whether C2B8 will be used as a front
line treatment is difficult to say. Certainly, C2B8/Chemo which was tested as a frontline treatment showed exciting results and any analyst who is recommending any exciting but speculative company will definantly error on the side of conservatism as far as earnings projections. I personally don't put much weighting on an analysts eps projectons involving a biotech company introducing a new product. There are just too many unknowns and these numbers normally are updated with time and in many cases they are far from the original data. What I am curious to know is how efficacious will C2B8 be on retreatments, which would obviously increase the market potential.. I agree with your comments concerning Coulter and indeed they have produced exciting results. I noticed in First Bostons latest report that Shekar Basu mentioned a conference that will take place this month and there will be results on YB28. I was unaware of this, however, Idec did not confirm that this info was going to be available but rather there will be an update on the duration of responses on C2B8.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News